40 related articles for article (PubMed ID: 19450995)
1. The significance of erythrocyte sedimentation rate as a prognostic factor for patients with prostate cancer: Gunma Urological Oncology Study Group investigation.
Imai K; Suzuki T; Kobayashi M; Yamanaka H; Tomaru Y; Sato J
Jpn J Cancer Res; 1990 Oct; 81(10):971-4. PubMed ID: 2121683
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of
Soerohardjo I; Widodo I; Heriyanto DS; Zulfiqqar A; Anwar SL
Ann Med Surg (Lond); 2020 Dec; 60():549-554. PubMed ID: 33299560
[TBL] [Abstract][Full Text] [Related]
3. An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer.
Saxby H; Mikropoulos C; Boussios S
Diagnostics (Basel); 2020 Jul; 10(8):. PubMed ID: 32752137
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients.
Lin TT; Chen YH; Wu YP; Chen SZ; Li XD; Lin YZ; Chen SH; Zheng QS; Wei Y; Xu N; Xue XY
J Cancer; 2019; 10(22):5608-5613. PubMed ID: 31632505
[No Abstract] [Full Text] [Related]
5. Effects of ellagic Acid on angiogenic factors in prostate cancer cells.
Vanella L; Di Giacomo C; Acquaviva R; Barbagallo I; Li Volti G; Cardile V; Abraham NG; Sorrenti V
Cancers (Basel); 2013 Jun; 5(2):726-38. PubMed ID: 24216999
[TBL] [Abstract][Full Text] [Related]
6. Clinical features and treatment strategies for older prostate cancer patients with bone metastasis.
Yang C; Qi GS; Rong RM; He J
Asian J Androl; 2013 Nov; 15(6):759-63. PubMed ID: 24036918
[TBL] [Abstract][Full Text] [Related]
7. Profiling of the calcitonin-calcitonin receptor axis in primary prostate cancer: clinical implications and molecular correlates.
Thakkar A; Bijnsdorp IV; Geldof AA; Shah GV
Oncol Rep; 2013 Sep; 30(3):1265-74. PubMed ID: 23820954
[TBL] [Abstract][Full Text] [Related]
8. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool.
De Nunzio C; Leonardo C; Franco G; Esperto F; Brassetti A; Simonelli G; Dente D; De Dominicis C; Tubaro A
World J Urol; 2013 Apr; 31(2):365-9. PubMed ID: 22576696
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and prognostic factors for patients with bone metastases from prostate cancer.
He J; Zeng ZC; Yang P; Chen B; Jiang W; Du SS
Asian J Androl; 2012 May; 14(3):505-8. PubMed ID: 22504872
[TBL] [Abstract][Full Text] [Related]
10. Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial.
Uemura H; Yanagisawa M; Ikeda I; Fujinami K; Iwasaki A; Noguchi S; Noguchi K; Kubota Y;
Int J Clin Oncol; 2013 Jun; 18(3):472-7. PubMed ID: 22491982
[TBL] [Abstract][Full Text] [Related]
11. [Bone metastasis in prostate cancer].
Moltzahn F; Thalmann GN
Urologe A; 2012 Jan; 51(1):20-6. PubMed ID: 22258372
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
15. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in metastatic prostate cancer.
Yigitbasi O; Ozturk U; Goktug HN; Gucuk A; Bakirtas H
Urol Oncol; 2011; 29(2):162-5. PubMed ID: 19450995
[TBL] [Abstract][Full Text] [Related]
17. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
